Table 1 Baseline characteristics of the study cohorts at the time of the second vaccination, N = 1118.

From: Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults

Characteristics

Study-cohorts after second vaccination

BB-3

N = 248

BB-6

N = 262

AA-12

N = 265

AB-12

N = 343

Interval between first to second vaccination—weeks

3

6

12

12

Median interval between second to booster—vaccination (range)—weeks

42 (33–46)

30 (24–32)

26 (22–31)

26 (22–29)

Median age

46

46

52

46

(IQR; range)—years

(35–53.5; 19–64)

(32–56; 19–73)

(39.5–59; 21–70)

(34.5–54; 18–71)

Sex—n (%)a

 Male

93 (38)

50 (19.5)

59 (22.7)

55 (16.8)

 Female

152 (62)

207 (80.5)

201 (77.3)

273 (83.2)

Median BMI

25.2

24.8

24.9

24.9

(IQR; range)—kg/m2

(22.9–29.1; 19–43)

(22.3–28.6; 16–52)

(22.3–28.7; 17–50)

(22.4–28.8; 16–46)

Occupational group—n (%)a

 Nursing

129 (53.3)

40 (17.6)

120 (50.2)

105 (37.1)

 Physicians

86 (35.5)

32 (14.1)

13 (5.4)

37 (13.1)

 Other hospital professions

27 (11.2)

155 (68.3)

106 (44.4)

141 (49.8)

  1. Baseline immunizations (first and second vaccination) were performed with m-RNA vaccine BNT162b2 (BioNTech/Pfizer, Mainz, Germany; B) and vector-based vaccine ChAdOx1-S (AstraZeneca, Wilmington, DE; A). In each case, cohort designations are composed of the first and second vaccines (A and B, respectively) and the interval between first and second vaccinations (in weeks).
  2. aNumerical differences between individual characteristics and the total population are due to missing information in the questionnaire.
Back to article page